Canaccord analyst Whitney Ijem lowered the firm’s price target on Tenaya Therapeutics to $18 from $21 and keeps a Buy rating on the shares. The analyst said the 4Q report was uneventful with pipeline timelines on track versus. what was announced in January.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on TNYA:
- Tenaya Therapeutics price target lowered to $18 from $25 at H.C. Wainwright
- Tenaya Therapeutics reports Q4 EPS (61c), consensus (65c)
- Tenaya Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
- 3 Stocks Insiders Love
- Tenaya Therapeutics management to meet virtually with Piper Sandler
